Navigation Links
Reportlinker Adds 2010 Pharmaceuticals Research Review
Date:12/14/2010

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

2010 Pharmaceuticals Research Review

http://www.reportlinker.com/p0341171/2010-Pharmaceuticals-Research-Review.html

FOREWORD The economic slowdown has accentuated the fault lines already dividing the pharmaceutical world. Lack of innovation from the large pharma companies, coupled with the patent expiration precipice, has fueled merger and acquisition activity. The in-licensing deals that mirror this trend have been a positive boon for biotech companies with either promising compounds in their pipeline, or promising platforms – most especially for delivering RANi drugs, or uncovering pathways previously held within the domain of academia only.

As a shadow looming behind this field there have also been dramatic change to U.S. health policy through legislation, and the awakening of the increasingly alluring emerging markets in China and India – still small in comparison - but future engines for high growth.

BCC Research has provided comprehensive coverage of pharmaceutical markets for many years, and we are now increasing our production of these research reports. This review of pharmaceutical market research conducted in 2010 is meant to provide a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC was founded in 1971.

This review includes highlights from the following reports on pharmaceutical markets published BCC Research: 

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

Global Markets for Orphan Drugs

Drug-Device Combinations: The Global Market

Cardiovascular Therapeutic Drugs: Technologies and Global Markets

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Antipsychotic Drugs: Technologies and Global Markets

Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets

Oncology Adjuvants: Technologies and Global Markets

The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession.  The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.

Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.

The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%.  The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.

Chapter-1: FOREWORD

FOREWORD 1

Chapter-2: OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM031C):

INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2

REASONS FOR DOING THE STUDY 2

SCOPE OF REPORT 3

INTENDED AUDIENCE 4

INFORMATION SOURCES 5

RELATED BCC REPORTS 5

BCC ONLINE SERVICES 6

DISCLAIMER 6

SUMMARY 6

TABLE 1 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 ($ MILLIONS) 7

FIGURE 1 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, 2008-2014 ($ MILLIONS) 8

OVERVIEW 9

HISTORY AND CURRENT STATE OF OPHTHALMOLOGY DISEASE 9

Established Drug Classes in Ophthalmology 10

Emerging Drug Classes 10

VEGF-Trap Eye 10

Combination Therapies 11

Competition between VEGF Inhibitors in Wet AMD 11

TABLE 2 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN: PREVIOUS AND EXPECTED 12

Expected Outcome of CATT trial: Avastin v. Lucentis 12

Genetic Specifications of Ophthalmic Disease 13

TABLE 3 SUMMARY OF KNOWN GENES INFLUENCING DISEASE 14

Summary Pipeline of Drugs in Development 14

TABLE 4 RECENTLY APPROVED DRUGS, 2009 15

TABLE 5 SUMMARY PIPELINE FORECAST, 2012-2014 15

INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS 15

INDUSTRY STRUCTURE 15

Market Concentration and Price Sensitivity 16

TABLE 6 COMPANY BY DISEASE CLASS, 2009 REVENUE ($ MILLIONS) 17

Competitive Factors 17

TABLE 7 LARGE REVENUE, BRANDED DRUG SALES COMING OFF PATENT, 2009 18

Chapter-3: GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038C)

INTRODUCTION 19

STUDY GOAL AND OBJECTIVES 19

REASONS FOR DOING THE STUDY 20

INTENDED AUDIENCE 20

SCOPE OF REPORT 21

INFORMATION SOURCES AND METHODOLOGY 21

AUTHOR'S CREDENTIALS 22

RELATED REPORTS FROM BCC RESEARCH 22

SUMMARY 23

TABLE 8
GLOBAL ORPHAN DRUGS DEMAND BY VALUE, THROUGH 2014 ($ MILLIONS) 24

FIGURE 2 GLOBAL ORPHAN DRUGS DEMAND BY VALUE, 2008-2014 ($ MILLIONS) 25

OVERVIEW 25

DEFINITION OF AN ORPHAN DRUG 25

HISTORY OF ORPHAN DRUG LEGISLATION 26

First Legislation on Orphan Drugs 26

Amendments to the ODA 26

Bills Passed in 2002 Increased Funding and Established the Office of Rare Diseases 26

Orphan Drug Legislation — Global Status 26

INCENTIVES FOR ORPHAN DRUG DEVELOPMENT 27

THE NEED FOR INCENTIVES 27

TABLE 9 NUMBER OF ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR BY U.S. FDA, 1983-2009 27

APPLICATIONS FOR ORPHAN DRUG DESIGNATIONS HAVE DOUBLED 28

PROFITABILITY OF ORPHAN DRUGS 28

Market Exclusivity 28

No Regulatory Restrictions on Pricing 29

Off-Label Use 29

CHALLENGES FOR EFFECTIVE USE OF THE ODA 30

MARKET EXCLUSIVITY VERSUS PATENT PROTECTION 30

MARKET SIZE AND KEY PLAYERS 31

TABLE 10 TOP 10 COMPANIES IN THE ORPHAN DRUG MARKET AND THEIR MARKET SHARES (%) 32

THE ORPHAN DRUG ACT — A BONUS FOR BIOTECH 32

BIG PHARMA IS ENTERING THE ORPHAN DRUGS SECTOR AGGRESSIVELY 32

CONCERNS ABOUT THE ORPHAN DRUG ACT 33

COST-EFFECTIVENESS 34

PRICING OF ORPHAN DRUGS 34

TABLE 11 SOME EXAMPLES OF HIGHLY EXPENSIVE ORPHAN DRUGS AND THEIR PRICES 35

High-Priced Orphan Drugs Leading to Price Control Measures by Governments 36

TABLE 12 SOME OF THE RECENT CONTROVERSIES RELATED TO ORPHAN DRUGS PRICING 37

ACCESS TO ORPHAN DRUGS AND REIMBURSEMENT — CURRENT PRACTICES 38

Orphan Drug Access and Reimbursement Scenario in the U.S. 38

Access and Reimbursement Scenario in Europe 38

TABLE 13 ORPHAN DRUG ACCESS AND REIMBURSEMENT PRACTICES  IN EUROPEAN COUNTRIES 39

TABLE 13 (CONTINUED) 40

TABLE 13 (CONTINUED) 41

Call for Unification of Orphan Drug Access Across Europe 41

INNOVATIVE APPROACHES OF PRICING AND REIMBURSEMENT 42

TABLE 14 EMERGING TRENDS IN PRICING AND REIMBURSEMENT OF HIGH-PRICED DRUGS 42

TABLE 14 (CONTINUED) 43

Chapter-4: DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET (PHM045B)

INTRODUCTION 44

STUDY GOALS AND OBJECTIVES 44

REASONS FOR DOING THIS STUDY AND ITS IMPORTANCE 44

INTENDED AUDIENCE 45

SCOPE OF REPORT 45

METHODOLOGY AND INFORMATION SOURCES 45

ANALYST CREDENTIALS 46

SUMMARY 46

SCOPE OF THE INDUSTRY 46

DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET 47

TECHNOLOGY AND PATENT ACTIVITY 48

THE CENTRAL ROLE OF THE FDA 48

TABLE 15 SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2014 ($ BILLIONS) 49

FIGURE 3 SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2008-2014 ($ BILLIONS) 49

CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY 50

OVERVIEW 50

ROLE OF THE FDA 50

TABLE 16 RECENT EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS 51

TABLE 16 (CONTINUED) 52

OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL STRUCTURE 52

HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE 52

EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS 53

FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS 54

TABLE 17 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS 55

THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS 55

FDA TRENDS IN REVIEWING COMBINATION PRODUCTS 55

FIGURE 4 COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2007 (NUMBER OF SUBMISSIONS) 56

TABLE 18 FDA COMBINATION PRODUCT CATEGORIES, FY 2004 57

TABLE 19 FDA COMBINATION PRODUCT CATEGORIES, FY 2005 (NUMBERS AND TYPES OF COMBINATION PRODUCTS) 58

NANOTECH COMBINATION PRODUCTS 59

OVERVIEW 59

NATIONAL NANOTECHNOLOGY INITIATIVE (NNI) 59

NANOTECH REGULATORY ENVIRONMENT 60

Nanotech Regulatory Environment (Continued) 61

COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH 62

Nanodiamond Drug Devices for Cancer Treatment 63

Nanotechnology-Magnetism Combination in Tiny Implantable Device for Drug Delivery 64

Implants Using Conducting Polymer Nanotubes 65

Calcium Phosphate Nanoparticles for Drug Delivery 66

Nano-scale Delivery Optimizes Chemotherapy Regimes 67

Drug Infused Nanoparticles 68

Drug Infused Nanoparticles (Continued) 69

Encapsulation of Drug Treatments in Nanoparticles 70

Silicon Nanowires for Drug Delivery 70

Minute Antibacterial Particles Destroy Drug-Resistant Germs 71

Biodegradable Cationic Core-Shell Nanoparticles for Co-delivery of Drugs and Genes 72

Stimuli-Sensitive Core-Shell Nanoparticles for Cancer Therapy 72

Polymer-Based Non-Viral Gene Carriers 73

POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY 73

Potential Health Effects: … (Continued) 74

TABLE 20 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATIONS, THROUGH 2014 $ MILLIONS 75

Chapter-5: CARDIOVASCULAR THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM024B)

INTRODUCTION 76

STUDY GOALS AND OBJECTIVES 76

REASONS FOR DOING THE STUDY 76

SCOPE OF REPORT 77

INTENDED AUDIENCE 78

METHODOLOGY AND INFORMATION SOURCES 79

RELATED BCC REPORTS 79

BCC ONLINE SERVICES 79

DISCLAIMER 80

SUMMARY 80

TABLE 21 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 80

FIGURE 5 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, 2007-2015 ($ MILLIONS) 81

OVERVIEW 82

CURRENT STATE OF CARDIOVASCULAR DISEASE 82

FIGURE 6 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006 (DEATHS PER 100,000) 83

ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE 84

Statins 84

Angiotensin Receptor Blocker 85

Angiotensin Converting Enzyme (ACE) inhibitors 85

EMERGING DRUG CLASSES 86

P2Y12 Inhibitors and Antagonists 86

Factor Xa Inhibitors 86

Cholesterol-Ester Transfer Protein (CETP) Inhibitor 87

TABLE 22 CETP INHIBITORS IN ACTIVE DEVELOPMENT 87

KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET 87

Plavix Metabolizer 2C19 Triggers U.S. Warning 87

VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION 88

SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 89

TABLE 23 RECENTLY APPROVED DRUGS 89

TABLE 24 SUMMARY PIPELINE FORECAST 90

INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS 90

INDUSTRY STRUCTURE 90

TABLE 25 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 ($ MILLIONS) 91

MARKET CONCENTRATION AND PRICE SENSITIVITY 92

TABLE 26 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS) 93

MARKET TRENDS 94

Overall Market Flat: Higher Mix of Generics Offset by Higher Volume 94

MASSIVE PATENT EXPIRATION IS A GROWTH OPPORTUNITY FOR GENERICS 94

TABLE 27 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($ MILLIONS) 95

MARKET EXPANSION VIA DISEASE PREVENTION IS THE FUTURE OF CARDIO CARE 95

ATRIAL FIBRILLATION IS A LARGE AND EMERGING DISEASE STATE 96

COMBINATION THERAPIES ARE SYNERGISTIC REVENUE GENERATORS 97

COMBINATION THERAPIES ARE …(CONTINUED) 98

Chapter-6: ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS (PHM062A)

INTRODUCTION 99

STUDY GOALS AND OBJECTIVES 99

REASONS FOR DOING THIS STUDY 99

SCOPE OF REPORT 99

INTENDED AUDIENCE 100

METHODOLOGY 100

INFORMATION SOURCES 100

ANALYST CREDENTIALS 100

RELATED BCC REPORTS 100

SUMMARY 101

TABLE 28 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 101

FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-2014 ($ MILLIONS) 101

FORECAST SUMMARY 102

OVERVIEW 103

DEFINITION AND MARKET STRUCTURE 103

What Is Alzheimer's Disease? 103

TABLE 29 U.S. ALZHEIMER'S PATIENTS, 2000–2050 (MILLIONS) 103

FIGURE 8 U.S. ALZHEIMER'S PATIENTS, 2000–2050 (MILLIONS) 104

Role of the Cholinergic System 104

Role of Beta-Amyloid Protein 105

Behavioral Manifestations of AD 106

Incidence and Prevalence 106

TABLE 30 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009–2050 (MILLIONS) 106

TABLE 31 PERCENT POPULATION OVER 65, BY REGION (%) 107

TABLE 32 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 107

FIGURE 9 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 107

TABLE 33 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET 108

FIGURE 10 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET (%) 108

TABLE 34 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 108

STAGES OF ALZHEIMER'S DISEASE 109

Stages of Alzheimer's … (Continued) 109

Stages of Alzheimer's … (Continued) 109

DIAGNOSIS 111

TABLE 35 DIAGNOSTIC TESTS 112

How Accurate are the Screening Tests? 112

How Accurate are the … (Continued) 113

KEY EVENTS 114

PATENT EXPIRATIONS 114

NEW PRODUCT LAUNCHES 114

PRICING 115

KEY MARKETS 115

TABLE 36 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, THROUGH 2014 ($ MILLIONS) 115

FIGURE 11 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2008-2014 ($ MILLIONS) 116

MARKET SIZE AND KEY PLAYERS 116

Chapter-7: ANTIPSYCHOTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM063A)

INTRODUCTION 117

STUDY GOALS AND OBJECTIVES 117

REASONS FOR DOING THIS STUDY 118

INTENDED AUDIENCE 118

SCOPE OF REPORT 119

METHODOLOGY 119

INFORMATION SOURCES 120

AUTHOR'S CREDENTIALS 120

RELATED BCC WORK CREDENTIALS 120

SUMMARY 120

TABLE 37 THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, THROUGH 2014 ($, MILLIONS) 121

FIGURE 12 THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, 2010–2014 ($, MILLIONS) 122

OVERVIEW 122

DEFINITION OF AN ANTIPSYCHOTIC DRUG 122

HISTORY OF ANTIPSYCHOTIC DRUGS 123

History of Antipsychotic Drugs 124

TYPES OF ANTIPSYCHOTICS ON THE MARKET 125

TYPICAL ANTIPSYCHOTICS 125

TABLE 38 CLASSES OF TYPICAL ANTIPSYCHOTICS ON THE MARKET AND THEIR SIDE EFFECTS 126

ATYPICAL ANTIPSYCHOTICS 127

TABLE 39 CURRENTLY APPROVED ATYPICAL ANTIPSYCHOTICS ON THE MARKET 128

TABLE 39 (CONTINUED) 129

TABLE 40 FEATURES OF TYPICAL VERSUS ATYPICAL ANTIPSYCHOTICS 130

TABLE 41 COST OF SELECTED ATYPICAL AND TYPICAL ANTIPSYCHOTIC DRUGS ($) 130

TABLE 41 (CONTINUED) 131

RECEPTOR TARGETS OF ANTIPSYCHOTIC DRUGS 131

DOPAMINE 131

SEROTONIN 132

GLUTAMATE 133

TACHYKININ 134

GLUCOCORTICOID 135

SIDE EFFECTS OF ANTIPSYCHOTICS 135

NEUROLOGIC SIDE EFFECTS (EXTRAPYRAMIDAL SYMPTOMS) 135

ANTICHOLINERGIC SIDE EFFECTS 136

CARDIOVASCULAR SIDE EFFECTS 137

METABOLIC SIDE EFFECTS 138

OTHER SIDE EFFECTS 138

TABLE 42 COMPARISON OF SIDE EFFECT PROFILES OF ANTIPSYCHOTICS ON THE MARKET 139

ANTIPSYCHOTICS IN CLINICAL DEVELOPMENT 139

TABLE 43 ANTIPSYCHOTICS IN CLINICAL TRIALS, ORDERED BY PHASE 140

TABLE 43 (CONTINUED) 141

TABLE 44 NUMBER OF ANTIPSYCHOTICS IN CLINICAL TRIALS, BY PHASE (NUMBER/%) 141

FIGURE 13 ANTIPSYCHOTICS IN CLINICAL TRIALS BY PRIMARY RECEPTOR TARGET 142

TABLE 45 COMPANIES WITH MORE THAN ONE ANTIPSYCHOTICS IN CLINICAL TRIALS OR ON THE MARKET* 143

Chapter-8: UBIQUITIN PROTEOSOME DRUGS: CANCER AND NEURODEGENERATIVE DISORDER

INTRODUCTION 144

STUDY GOALS AND OBJECTIVES 144

REASONS FOR DOING THIS STUDY 144

SCOPE OF REPORT 144

METHODOLOGY AND INFORMATION SOURCES 145

INTENDED AUDIENCE 145

ANALYST CREDENTIALS 145

RELATED BCC REPORTS 146

SUMMARY 146

TABLE 46 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 ($ MILLIONS) 147

FIGURE 14 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 ($ MILLIONS) 148

FIGURE 15 GLOBAL MARKET SHARES OF MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANIES, 2009 (%) 148

FIGURE 15 (CONTINUED) 149

OVERVIEW OF SCIENTIFIC BACKGROUND, AND SIGNIFICANCE OF UPS RESEARCH 149

UBIQUITINATION PHENOMENA AND ITS MAJOR COMPONENTS 149

Enzymatic Components as Possible Drug Targets 149

TABLE 47 ENZYMATIC COMPONENTS OF UBIQTUINATION/ DEUBIQUITINATION REACTION 150

FIGURE 16 ENZYMATIC STEPS IN UBIQUITINATION REACTION 150

FIGURE 17 HIERARCHICAL STRUCTURE OF UPS 151

Chain Topology as a Signaling Pathway 151

PROTEASOME MACHINERY 152

STRUCTURE AND FUNCTION 152

PROTEASOME AS A TARGET FOR DRUG DISCOVERY 153

UBIQUITIN-LIKE MODIFIERS (UBLS) 153

TABLE 48 UBLS, THEIR FUNCTION AND ASSOCIATED PATHOLOGY WITH THEIR DYSFUNCTION 154

MAJOR DRUG DEVELOPMENT AND PRODUCTS IN THE UPS RESEARCH FIELD 155

INDUSTRY OVERVIEW 155

Proteasome as a Drug Discovery 155

Velcade: The First UPS Product 155

Chemical Structure of Velcade and Its Mechanism of Action 156

FIGURE 18 CHEMICAL STRUCTURE OF BORTEZOMIB 156

Pharmacodynamics, Administration, and Side Effects 156

Velcade Sales Market 157

Overview 157

TABLE 49 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2009 (NUMBER) 157

MM Symptoms and Treatment 158

General Treatment for MM Today 158

TABLE 50 PROJECTED SIZE OF THE WORLDWIDE MM DRUG MARKET, 2009 AND 2018 ($ BILLIONS) 159

NHL and Mantle Cell Lymphoma 159

·
Treatments for Mantle Cell Lymphoma and Other NHL 159

·
CHOP Therapy 159

·
MabThera/Rituxan 159

Current Major Market Participants in MM Treatment and Sales Forecast 160

Millennium Pharmaceuticals (a Subsidiary of Takeda) 160

TABLE 51 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 ($ MILLIONS) 160

FIGURE 19 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 ($ MILLIONS) 161

Celgene 161

·
Revlimid 161

·
Thalomid 162

TABLE 52 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, THROUGH 2016 ($ MILLIONS) 162

FIGURE 20 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, 2006-2016 ($ MILLIONS) 163

Market Shares of Millennium/Takeda, Celgene, and Other Companies' Drugs 163

TABLE 53 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO THOSE PROJECTED IN 2011* (%) 164

FIGURE 21 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO PROJECTED SHARES IN 2011* (%) 164

FIGURE 21 (CONTINUED) 165

Millennium Pharmaceuticals/Takeda's New Developments 165

TABLE 54 EXAMPLE OF COSTS OF SIDE EFFECTS OF CHEMOTHERAPY TREATMENT PER PATIENT IN THE U.S., 2006 ($ THOUSANDS) 166

New Formulations for Velcade and Second-Generation Inhibitors 166

Improvement of Velcade 166

Second-Generation Inhibitor MLN9708 166

TABLE 55 CURRENT R&D ACTIVITY IN UPS BY MILLENNIUM/TAKEDA 167

Velcade in Combination with Other Treatments 167

COMPANIES WORKING ON SECOND-GENERATION PROTEASOME INHIBITORS 167

OVERVIEW 167

Current Market Participants 167

TABLE 56 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET 168

Millennium Pharmaceuticals (a Subsidiary of Takeda) 168

Onyx Pharmaceuticals/Proteolix 168

·
Carfilzomib 168

·
ONX 0912 169

·
ONX 0914 (PR-957) 169

TABLE 57 WORLDWIDE MARKET FOR AUTOIMMUNE DISORDERS: LUPUS, RA, AND IBD, 2008 ($ BILLIONS) 170

Cephalon 170

• CEP-18770 170

Nereus Pharmaceuticals 170

• Salinosporamide (NPI-0052) 170

Salinosporamide … (Continued) 171

Chapter-9: ONCOLOGY ADJUVANTS: TECHNOLOGIES AND GLOBAL MARKETS (PHM067A)

INTRODUCTION 172

STUDY GOALS AND OBJECTIVES 172

REASONS FOR DOING THIS STUDY 172

INTENDED AUDIENCE 173

SCOPE OF REPORT 173

METHODOLOGY 173

INFORMATION SOURCES 174

ANALYST CREDENTIALS 174

RELATED BCC REPORTS 174

SUMMARY 174

TABLE 58 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS, THROUGH 2015 ($ MILLIONS) 175

FIGURE 22 GLOBAL ONCOLOGY ADJUVANT SALES BY MARKET GEOGRAPHY, 2009 AND 2015 (%) 176

OVERVIEW 177

HISTORY AND CURRENT STATE OF ONCOLOGY AND CONCEPTS OF ADJUVANTS IN ONCOLOGY 177

TYPES OF CANCER 178

DEFINITION OF THE INDUSTRY 179

IMPORTANCE OF THE INDUSTRY 180

PRODUCT LIFE CYCLES 180

TABLE 59 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG 181

DEVELOPMENT OF ONCOLOGY ADJUVANTS 181

TABLE 60 HISTORICAL PIPELINE OF FDA-APPROVED ONCOLOGY ADJUVANTS 182

HUMAN CLINICAL DEVELOPMENT 183

NEW DRUG ACTIVITY 183

FUTURE DEVELOPMENTS 184

2008 TO 2009 DRUG ACTIVITY 184

2008 to 2009 Drug Activity (Continued) 185

WITH AN EYE TOWARD THE FUTURE 186

TYPE OF APPLICATIONS IN THE HUMAN ONCOLOGY ADJUVANT MARKETPLACE: CHEMOTHERAPY, IMMUNOTHERAPY, AND RADIOTHERAPY 186

TABLE 61 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS SALES BY PRODUCT TYPE, THROUGH 2015 ($ MILLIONS) 187

FIGURE 23 ONCOLOGY ADJUVANTS SALES: BY ADJUNCTIVE PRODUCT TYPE, 2008-2015 ($ MILLIONS) 188

HUMAN CANCERS 188

TABLE 62 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS BY CANCER INDICATION, THROUGH 2015 ($ MILLIONS) 189

FIGURE 24 ONCOLOGY ADJUVANTS FORECAST SALES: BY TYPE OF CANCER 2008-2015 ($ MILLIONS) 189

RISK FACTORS FOR DEVELOPING CANCERS 190

TABLE 63 RISK FACTORS ASSOCIATED WITH HUMAN CANCERS 190

TABLE 63 (CONTINUED) 191

TABLE 64 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN MEN 192

TABLE 65 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN WOMEN 192

TABLE 66 HUMAN CANCER TRENDS, ESTIMATED, 2008-2015 (NUMBER OF CASES) 193

BREAST 193

TABLE 67 GLOBAL SALES FORECAST OF BREAST CANCER ONCOLOGY ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 194

RECTUM AND COLON 194

TABLE 68 GLOBAL SALES FORECAST OF COLORECTAL CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 195

NON-HODGKIN LYMPHOMAS 195

TABLE 69 GLOBAL SALES FORECAST OF LYMPHOMAS ADJUVANTS BY GEORGRAPHY, THROUGH 2015 ($ MILLIONS) 196

LUNG 196

TABLE 70 GLOBAL SALES FORECAST OF LUNG CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 197

LEUKEMIA 197

TABLE 71  GLOBAL SALES FORECAST OF LEUKEMIA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 198

PROSTATE CANCER 198

TABLE 72 GLOBAL SALES FORECAST OF PROSTATE CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 198

GLIOBLASTOMA 199

TABLE 73 GLOBAL SALES FORECAST OF GLIOBLASTOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 199

MULTIPLE MYELOMA 199

TABLE 74 GLOBAL SALES FORECAST OF MULTIPLE MYELOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 200

To order this report:Pharmaceutical Industry: 2010 Pharmaceuticals Research Review

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact Nicolas Bombourg: nbo@reportlinker.comUS: (805)-652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Obstetrics Partnering ... company profile to their offering. --> ... of the "Global Obstetrics Partnering 2010-2016: ... profile to their offering. --> ...
(Date:2/4/2016)... 2016 Worldwide Radiology Oncology surgical robot ... next generation systems provide a way to improve ... surgery. New systems pinpoint the delivery of radiation ... such a problem previously, limiting the quantity of ... cancer surgery far beyond what has been available, ...
(Date:2/4/2016)... -- Montoya Love is recognized by Continental Who,s Who as ... is the Regulatory Systems Operations Manager with Becton ... Manufacturing and selling a broad range of medical ... institutions, clinical laboratories and life science researchers with the ... An ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Ben Amini, a San ... welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the addition of services ... including general dentistry, cosmetic treatments, periodontics, implant dentistry , endodontics, orthodontics and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic ... in the event they are experiencing an illness. Migraines are a severe form of ... afflicted with migraines would not wish the pain on their worst enemy, the feeling ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
(Date:2/5/2016)... ... February 05, 2016 , ... Susan Polk Health Insurance Company recently ... expect to see in 2016. To view the report, see below, or visit ... many San Luis Obispo seniors who rely on Medicare health insurance and whose monthly ...
Breaking Medicine News(10 mins):